Pharmacist's Influence on Breast Cancer Patient Quality of Life

Influence of a Clinical Pharmacist's Intervention on Quality of Life of a Breast Cancer Patient Under Adjuvant Chemotherapy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02746666

Acronym

PIBC

Enrollment

Registered

2016-04-21

Start date

2016-04-30

Completion date

2016-06-30

Last updated

2016-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Quality of Life

Brief summary

The purpose of this study is to investigate the impact of pharmacist behavioral intervention's influence on breast cancer patients' quality of life. Croatian randomized controlled trial. Targeted population: general population of breast cancer patients under the first adjuvant anthracycline chemotherapy. Primary outcome: difference in EORTC QLQ-BR23 questionnaire result from the baseline to after 3 week cycle.

Interventions

BEHAVIORALPharmacist's behavioral intervention

Pharmacist's 30 min counselling on antiemetic therapy, causes of nausea or vomiting and ways to prevent them during chemotherapy.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Early breast cancer * First adjuvant chemotherapy * Chemotherapy protocol: anthracycline x 4

Exclusion criteria

* Cardiovascular comorbidities * Regular nausea or vomiting during six months before enrollment * Unable to answer the quality of life questionnaire on their own

Design outcomes

Primary

Measure	Time frame
changes in quality of life of a breast cancer patient under chemotherapy, after a clinical pharmacist's behavioral intervention, measured by EORTC B23 questionnaire	up to two months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026